Payers, pharmacies and pharmaceutical companies are starting to join providers in recognizing that social determinants of health (SDOH) have a major impact on patient adherence and clinical outcomes. Healthcare organizations now face the challenge of finding ways to analyze and…
Read
AllazoHealth Insights
Keep up with the latest insights and information on our blog. Find best practices, data and outcomes, and healthcare industry information, all from the experts and leaders at AllazoHealth.
Browse by topic
Subscribe to our news
4 keys to a successful medication adherence program
on July 7, 2020
| By
AllazoHealth
With medication non-adherence costing the industry more than $600 billion a year, many pharmaceutical companies are creating medication adherence programs, often in conjunction with pharmacists and payers. According to Andrea Kasprzyk, Director of Sales at AllazoHealth, “The objective of an…
Read
How pharmacies can make adherence cost-effective
on June 30, 2020
| By
AllazoHealth
Incentives drive pharmacy focus on adherence As pharmacies are increasingly held to quality incentives, they are getting proactive about adherence. For example, in March 2019, Walgreen Co. started hiring pharmacists specifically tasked with helping chronic disease patients to become more…
Read
How new patient data rules benefit payers
on June 23, 2020
| By
AllazoHealth
Starting next year payers may have new opportunities to collect real world data that was previously fragmented, incomplete and in some cases unavailable. According to the rules going into effect January 1, 2021 by the U.S. Department of Health and…
Read
Can copay assistance increase adherence?
on June 16, 2020
| By
AllazoHealth
Besides being a financial issue for pharmaceutical companies, unfilled prescriptions can lead to poorer health outcomes, drive up overall cost of care, and can have an impact on provider performance under value-based payment models. Pharmaceutical companies often use copay assistance…
Read
AllazoHealth names pharmacy benefits management leader Greg Watanabe to advisory board
on June 10, 2020
| By
AllazoHealth
AllazoHealth, a company that uses artificial intelligence to help pharmaceuticals, payers, and pharmacies improve medication adherence and quality outcomes, announced that pharmacy benefits management executive Greg Watanabe will be joining the company’s Advisory Board. Mr. Watanabe has a distinguished career…
Read
How smart pill bottles improve adherence
on June 2, 2020
| By
AllazoHealth
A smart pill bottle platform improved adherence and patient satisfaction among a small sample of multiple myeloma patients, according to a paper in the November 2019 issue of the Journal of Managed Care & Specialty Pharmacy. The study was conducted…
Read
Dispelling the myths of artificial intelligence in healthcare
on May 27, 2020
| By
AllazoHealth
As common as artificial intelligence has become in our daily lives — from Google’s Alexa, to Facebook’s data-driven ads, to Waze’s application of driver data to find the best route — it is little understood. The public tends to believe…
Read
Study with large regional payer demonstrates 5.45x greater adherence uplift using AI
on May 19, 2020
| By
AllazoHealth
Partnering with Blue Cross Blue Shield of North Carolina on a randomized control trial, AllazoHealth demonstrated a 5.5 times uplift in adherence compared with traditional programs. In addition, the study showed our artificial intelligence (AI) engine delivered over 97% accuracy…
Read
COVID-19: Surveys show payers intensifying patient outreach
on May 12, 2020
| By
AllazoHealth
What do payers consider as they grapple with the medication access and adherence needs of at-risk patients during the Covid-19 pandemic? Experts at McMann Managed Markets and Syneos Health surveyed their proprietary payer advisory boards to find out. Payers respond…
Read
Changes to SUPD in the COVID-19 era
on May 2, 2020
| By
AllazoHealth
Even in the midst of COVID-19 concerns and changes in healthcare practice, payers and pharmacies need to continue to be focused on the CMS Star quality care measures. One measure in particular, the Part D “Statin Use for Persons with…
Read
current_page_num+2: 2 -